PASITHEA THERAPEUTICS CORP. Proceeds from Debt, Net of Issuance Costs
PASITHEA THERAPEUTICS CORP. (KTTA) reported Proceeds from Debt, Net of Issuance Costs of $27.17 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2023-03-30
- PASITHEA THERAPEUTICS CORP. proceeds from debt, net of issuance costs for the quarter ending 2021-12-31 was $5.30M.
- PASITHEA THERAPEUTICS CORP. proceeds from debt, net of issuance costs for the quarter ending 2021-09-30 was $20.65M.
- PASITHEA THERAPEUTICS CORP. proceeds from debt, net of issuance costs for the quarter ending 2021-06-30 was $0.00.
- PASITHEA THERAPEUTICS CORP. proceeds from debt, net of issuance costs for the quarter ending 2021-03-31 was $1.21M.
- PASITHEA THERAPEUTICS CORP. proceeds from debt, net of issuance costs for fiscal 2021 was $27.17M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 8 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month | Proceeds from Debt, Net of Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $25.96M derived: sum of 2 quarters · filed 2023-03-30 | $25.96M derived: sum of 3 quarters · filed 2023-03-30 | $27.17M 10-K · filed 2023-03-30 | $1.21M 10-K · filed 2022-03-30 | |
| 2021-09-30 | $20.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $20.65M derived: sum of 2 quarters · filed 2022-11-14 | $21.86M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.21M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $1.21M 10-Q · filed 2022-05-16 | |||||
| 2020-12-31 | $282.34K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |